Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease
Strugnell SA, Sprague SM, Ashfaq A, Petkovich M, Bishop CW
American journal of nephrology · 56 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2019-01-01 · Am J Nephrol · vol. 49 · número 4 · págs. 284–293
- Editorial
- Karger Publishers
- Citado
- 74 citas · más que el 97% de estudios similares · 5.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 42 trabajos
- Acceso
- De pago
- Áreas de investigación
- Parathyroid Disorders and Treatments · Vitamin D Research Studies · Thyroid Disorders and Treatments
- Palabras clave
- Secondary hyperparathyroidism, Medicine, Vitamin D and neurology, Internal medicine, Kidney disease, Endocrinology, Renal function, Parathyroid hormone, Paricalcitol, Calcifediol, Hyperparathyroidism, Creatinine, Fibroblast growth factor 23, Placebo, Urology, vitamin D deficiency, Calcium, Pathology
- MeSH
- humans, vitamin d deficiency, hyperparathyroidism, secondary, calcifediol, parathyroid hormone, vitamin d, drug monitoring, double-blind method, reference values, aged, middle aged, female, male, renal insufficiency, chronic, practice guidelines as topic, fibroblast growth factor-23
5 autores
- Stephen A. Strugnell🇺🇸OPKO Health (United States)
- Stuart Michael Sprague🇺🇸Endeavor Health
- Akhtar Ashfaq🇺🇸OPKO Health (United States)
- Martin P. Petkovich🇨🇦Queen's University
- Charles W. Bishop🇺🇸OPKO Health (United States)
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Vitamin D repletion is recommended for secondary hyperparathyroidism (SHPT) and associated vitamin D insufficiency (VDI) in chronic kidney disease (CKD), but optimal levels of serum total 25-hydroxyvitamin D remain undefined. Clinical practice guidelines target sufficiency, whereas recent data indicate that higher levels are required to control the elevation of intact parathyroid hormone (iPTH) as CKD advances. This secondary analysis of 2 randomized controlled trials seeks to identify the minimum level of mean serum 25-hydroxyvitamin D required to control SHPT arising from VDI in stage 3 or 4 CKD.
Methods
Adult subjects (n = 429) with SHPT, VDI, and stage 3 or 4 CKD were stratified by stage and treated daily with either extended-release calcifediol (ERC) or placebo in 2 identical, parallel, randomized, double-blind studies. After treatment for 26 weeks, all subjects were ranked by the level of serum total 25-hydroxyvitamin D and divided into quintiles in order to examine the relationships between the degree of vitamin D repletion and the associated changes in plasma iPTH, serum bone turnover markers, calcium, phosphorus, intact fibroblast growth factor 23 (FGF23) and vitamin D metabolites, estimated glomerular filtration rate (eGFR), and urine calcium:creatinine (Ca:Cr) ratio.
Results
Progressive increases in serum 1,25-dihydroxyvitamin D and reductions in plasma iPTH and serum bone turnover markers were observed as mean posttreatment serum 25-hydroxyvitamin D rose from 13.9 ng/mL (in Quintile 1) to 92.5 ng/mL (in Quintile 5), irrespective of CKD stage. Mean serum calcium, phosphorus and FGF23, eGFR, and urine Ca:Cr ratio (collectively "safety parameters") did not significantly change from Quintile 1. Suppression of iPTH and bone turnover markers was not observed until serum 25-hydroxyvitamin D rose to at least 50.8 ng/mL (Quintile 3).
Conclusion
ERC therapy produced exposure-dependent reductions in plasma iPTH and bone turnover markers only when mean serum total 25-hydroxyvitamin D reached at least 50.8 ng/mL, indicating that current targets for vitamin D repletion therapy in CKD are too low. Gradual elevation of mean serum 25-hydroxyvitamin D to 92.5 ng/mL was not associated with significant adverse changes in safety parameters.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.